Last reviewed · How we verify
Standard Care
Standard Care is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved. Also known as: usual care, Prochlorperazine, Reglan, Intravenous fluids.
Standard Care refers to the established, evidence-based treatment protocols and clinical management practices for a given disease or condition.
Standard Care is a treatment modality that involves interventions such as active-rtACS treatment, sham-rtACS treatment, and the DWELL Programme, which are being studied in various conditions including Acute Autoimmune Inflammatory Optic Neuritis, Type 2 Diabetes, and HIV/AIDS. Standard Care is a small molecule treatment modality, as classified by ChEMBL.
At a glance
| Generic name | Standard Care |
|---|---|
| Also known as | usual care, Prochlorperazine, Reglan, Intravenous fluids, Intubation if necessary, |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Standard Care is not a specific drug but rather a comparator arm or control group in clinical trials representing the current best-practice treatment available. It serves as the baseline against which investigational therapies are evaluated to demonstrate clinical benefit or superiority.
Approved indications
Common side effects
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure) (NA)
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Shared Decision-Making Decision Aid for Newly Diagnosed Breast Cancer : A Multi-Center Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Care CI brief — competitive landscape report
- Standard Care updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about Standard Care
What is Standard Care?
How does Standard Care work?
Who makes Standard Care?
Is Standard Care also known as anything else?
What development phase is Standard Care in?
Related
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Also known as: usual care, Prochlorperazine, Reglan, Intravenous fluids, Intubation if necessary,
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing